Search results
Found 27739 matches for
The collaboration brings the European Health Data & Evidence Network (EHDEN) together with the European Medicines Agency and partners.
©
Photo by KOBU agency on UnSplash
Botnar MRC iCase projects
iCase projects for entry in 2023. *Applications for these projects are now closed. New projects will be uploaded in Summer 2023*
Available projects
Applications are invited from 31 October - 9 December 2022
MEET DANI
-
Daniel Prieto-Alhambra
Professor of Pharmaco- and Device Epidemiology
Find out more about
Similar stories
The new Botnar strategy is announced
27 January 2023
After a year as the Director of the Botnar Institute for Musculoskeletal Sciences, Professor Jonathan Rees announces a new structure and strategy that will further enhance research and treatment of bone, joint and musculoskeletal conditions.
New global health grant to improve outcomes for patients with hip fracture
26 January 2023
Hip fracture patients in Low- and Middle-Income Countries (LMIC) in Asia are set to benefit from a new study that aims to bring best practice programmes to improve quality of life for patients and reduce healthcare costs.
NDORMS welcomes great-granddaughter of former Head of Department
20 January 2023
Julia Strubell, great-granddaughter of Professor Josep Trueta, visited NDORMS to find out about his time here and to share her own work with staff and students.
Botnar researchers awarded Fellowships
9 January 2023
Arani Vivekanantham has been awarded an NIHR Doctoral Fellowship and a Versus Arthritis Clinical Research Fellowship, and Rachel Kuo was awarded an NIHR Doctoral Research Fellowship.
Better diagnosis and treatment of autoimmune diseases moves a step closer
5 January 2023
A study published in Nature outlines a way to find the crucial peptides (protein fragments) that drive autoimmunity, as well as the immune cells that respond to them.
New drug offers hope for people with hand osteoarthritis
22 December 2022
A new study, published in Science Translational Medicine by researchers at the University of Oxford has identified that Talarozole, a drug that is known to increase retinoic acid, was able to prevent osteoarthritis (OA) in disease models.